News

An independent data monitoring committee (IDMC) has recommended the partnership to stop the trials of lanabecestat, as it is unlikely to meet primary endpoints. AstraZeneca IMED biotech unit

In addition, BridgeBio announced that it was launching a new subsidiary, Origin Biosciences, with sufficient capital to support clinical development of ALXN1101 through potential regulatory approval and commercialization.

ADXS-NEO is being evaluated in an open-label, dose-escalation, multicenter Phase 1 clinical trial in the United States. The study is open to patients with metastatic non-small cell lung

The two companies have entered into a multi-year research and development collaboration to develop the vaccines for a maximum of five undisclosed infectious disease pathogens. As per the

Tagrisso is a third-generation and irreversible EGFR-TKI designed to suppress both EGFR-sensitising and EGFR T790M-resistance mutations, with clinical activity against CNS metastases. The approval was based on data

Cellenkos submitted its IND application on May 11, 2018.  The Phase I clinical trial of CK0801 will commence in the third quarter of 2018 at The University of

Results were presented at the OxalEurope, European Hyperoxaluria Consortium, taking place on 8 June 2018 in Naples, Italy. Updated interim data were from Part B of the Phase

The approval for the drug regimen is for CLL and SLL patients, with or without 17p deletion, and who had received more than one prior therapy. Venclexta is

Oncologie is committed to developing impactful cancer therapies to improve long–term survival of cancer patients worldwide. Building a pipeline of First and Best-in-Class clinical stage drug candidates through